CTLA4 and neoplasm: Although all data herein support inhibited function of the tumor Tregs, there was no evidence of inhibited function of splenic Tregs since there was no change in a) CTLA-4 in splenic Tregs after 2 months of treatment in a model more likely to show changes, or b) in the ability of splenic Tregs to inhibit proliferation of T effector cells after 1–5 months of treatment.